Skip to main content
Skip to main content
Go to homepage

Grand Rounds: Pediatric Low-Grade Gliomas: From BRAF to Beyond

09-20-2019

By Jason Fangusaro, MD , Director, Developmental Therapeutics and Medical, Emory Univ. School of Medicine, Atlanta, GA

Urology

More about Eric Massanyi, MD


Objectives (Educational Content) :

1. Recognize the common characteristics of pediatric low-grade gliomas, including epidemiology, presentation, treatments and survival outcomes. 2. Recognize what is currently understood about pediatric low-grade glioma molecular biology, including aberrations in the MAPK pathway. 3. Describe what the current response rates and survival outcomes are utilizing MEK-1/2 inhibition strategies in recurrent pediatric low-grade gliomas.

Target Audience:

General pediatricians, family physicians, nurse practitioners, physician assistants, social workers, psychologists and nurses.

Identified Gap:

Current advances in research in the treatment of low-grade pediatric gliomas has improved patient outcome.

Estimated Time to Complete the Educational Activity:

1 hour

Expiration Date for CME Credit:

09-18-2020

Method of Physician Participation in the Learning Process:

The learner will view the presentation, successfully complete a post-test and complete an activity evaluation.

Evaluation Methods:

All learners must successfully complete a post-test, as well as an activity evaluation, to claim CME credit.

Disclosure:

Dr. Fangusaro has indicated that he has no relevant financial interest in any pharmaceutical or medical device company and does not intend to discuss any off-label uses of medications or medical devices in his presentation.

Accreditation Statement:

Children’s Hospital Medical Center of Akron is accredited by the Ohio State Medical Association to provide continuing medical education for physicians.

CHMCA designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

Bibliography:

Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A, Ligon KL, Massimino M, Meeteren SV, Mueller S, Nicolaides T, Perilongo G, Tabori U, Vezina G, Warren K, Witt O, Zhu Y, Jones DT, Kieran M. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol. 2016 Sep 28.

de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J.

Management of pediatric low-grade glioma. Curr Opin Pediatr. 2018 Dec 3. Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi MA. Phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC). Neuro-oncology, 2017 Feb 28